Abstract: The number of diabetic patients is increasing every year, and new model
Introduction
Many diabetic conditions have been researched, and many spontaneous and experimental diabetic model animals are currently used to research the human diabetic condition. However, new research animals are still needed to investigate the diverse aspects of the mechanism of diabetes. We discovered that MSG subcutaneously injected newborn mice developed glycosuria while breeding them for obesity research, and we were interested in the appearance of a diabetic condition (hyperglycemia, hyperinsulinemia, and hyperplastic islets), as well as diabetic complications in these mice in old age. It was reported that the ventromedial nucleus of the hypothalamus was destroyed by injecting mice with goldthioglucose (GTG) [6, 7] and that the injected mice showed polyphagia and obesity [8] , thereafter becoming diabetic. On the other hand, there are few reports of injecting MSG into mice that already have a diabetic condition [1, 9] , and also few reports concerning diabetes in other experimental animals [3, 5] . There is no report of ICR normal mice developing obesity without polyphagia and a diabetic condition by injecting MSG, and of the condition continuing over a long period. In this study, we injected mice with MSG and kept them for up to 54 weeks, examining the progress of obesity, glycosuria, and their diabetic condition by evaluating their pathology and blood biochemistry.
Materials and Methods

Animals
Newborns from five mice among 8 pregnant Crj:CD-1(ICR) mice purchased on the 12th day of pregnancy from Charles River Japan, Inc. were used. The newborns were divided into 4 groups according to treatment and sex. The birth date was the beginning of the injections, and MSG (Wako Pure Chemical Industries, Ltd., Tokyo) was subcutaneously injected (2 mg/g) to the male and female treatment groups (ICR-MSG mice) on consecutive days until 4 days old, while physiological saline was injected to the other male and female groups (control mice).
Mice were housed, 3-6 per TPX cages (230 × 310 × 155 mm, Okazaki Sangyo Co., Tokyo), according to their treatment groups in a non-barrier-sustained animal room maintained at 23 ± 2°C with 50 ± 10% relative humidity and a 12/12 h light / dark cycle. They were maintained on a basal diet (MF, Oriental Yeast Co., Ltd., Tokyo) and chlorinated water ad libitum. This study was performed in accordance with the Guidelines for Animal Experimentation of Tsumura & Co.
Food and water intake
The amount of spillage and chow in each cage was measured for 4 days at 6 weeks of age, and the average food and water intake of a mouse per day were calculated.
Urinalysis and blood chemistry
Urine collection was executed by compulsive urination every week from 7 to 29 weeks of age, and urinary glucose was determined by Amus urinalysis test paper (Labstix, Bayer Medical, Ltd.,Tokyo).
A blood sample (50 µl) was collected from the eye socket venous plexus of non-fasting mice by a capillary tube at 29 weeks of age and by cutting the cervical vertebrae at 54 weeks of age. It was diluted five times with physiological saline containing heparin and the plasma was preserved at -20°C after centrifugal separation. Blood glucose, blood insulin (B-Ins), total cholesterol (T-Cho), triglycerides (TG), low density lipoprotein cholesterol (LDL-Cho), high density lipoprotein cholesterol (HDL-Cho), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) densities were measured using a biochemical analyzer (TBA40FR, TOSHIBA Co., Tokyo). The concentration of blood insulin (B-Ins) was measured by a LBIS insulin measuring kit for mice (Shibayagi Co., Ltd., Gunma).
Glucose tolerance test (GTT) and insulin tolerance test (ITT)
A glucose tolerance test was made on 7 ICR-MSG male mice appearing to have urinary glucose at 10 weeks of age and 7 control male mice of the same age. After the mice had been fasted overnight, 2 g/kg of glucose was injected into their peritoneal cavity, and 20 µl of blood was collected from the eye socket venous plexus by a capillary tube at 0, 30, 60, and 180 min. The blood glucose level was measured by the above mentioned biochemical analyzer.
An insulin tolerance test was made on seven non-fasted ICR-MSG male mice appearing to have urinary glucose and 7 control male mice of the same age at 12 weeks of age. Twenty IU/kg of insulin (Novo Nordisk Pharma, Ltd., Tokyo) was injected into the peritoneal cavity, and 20 µl of blood was collected from their eye socket venous plexus by a capillary tube at 0, 30, 60, and 120 min. The blood glucose level was measured in the same way as in the glucose tolerance test, and the rate of decrease was calculated by comparison with data obtained immediately before the injection.
Body mass index (BMI)
At 29 weeks of age, mouse length from nose to anus was measured by calipers, the weight was recorded, and body mass index (BMI) was calculated by the equation [body weight (g) / body length 2 (cm)].
Organ weights and pathological examination
An anatomy inspection was made of all mice. Liver, pancreas, kidney, eye, sciatic nerve, visceral white adipose tissue (VWAT), interscapular brown adipose tissue (IBAT), aorta, and cerebrum were removed and weighed. Hematoxylin-eosin (HE) stained sections of these organs were made by routine processing after fixing with 15% phosphate buffered formalin solution, and were examined with an optical microscope.
Statistical analysis
Measurement data are shown as the mean value ± standard error (Mean ± SE), and the significance level of the statistical analysis was P<0.05 using Wilcoxon verification. Figure 1 shows the body weights from 3 to 29 weeks of age for the ICR-MSG and control mice. The weight of ICR-MSG mice from 3 to 5 weeks was lighter than the controls, however, the weight from 7 to 29 weeks was heavier than that of the controls. ICR-MSG female weight (52.6±1.2 g) at 29 weeks was increased 138.8% against the control females, and ICR-MSG male weight (62.8±1.6 g) at 29 weeks was increased 118.3% against the control males. The weight value of ICR-MSG female and male mice at 54 weeks of age did not differ from the controls.
Results
Body weight and BMI
ICR-MSG mice were significantly shorter in body length than the controls at 29 weeks of age. BMI of the ICR-MSG mice were, : female, 0.511 ± 0.011 g/ cm 2 and male, 0.582 ± 0.016 g/cm 2 ; both were significantly (each P<0.01) higher than the controls.
Food and water intake
Average ICR-MSG female food intake at 6 weeks was 3.9 g/day/mouse and for males was 4.5 g/day/ mouse. These amounts were almost the same as the controls. Average ICR-MSG female water intake at 6 weeks was 4.3 ml/day/mouse while ICR-MSG male intake was 5.4 ml/day/mouse. Again, these amounts were almost the same as the controls. No remarkable polyphagia or polydipsia was recognized among the groups from the average food and water intake at six weeks of age.
Glycosuria test
Glycosuria in ICR-MSG males started to appear from 8 weeks and was observed in 70.0% of them by the age of 29 weeks. The glycosuria of ICR-MSG females started to appear from 19 weeks and was observed in 29.4% of them by the age of 29 weeks. The appearance of glycosuria thus differed by sex in these mice in both period and percentage. No urinary glucose appeared in the control mice. Figure 2a ) shows that the blood glucose level of ICR-MSG males at 10 weeks of age was significantly higher than that of the controls. Glucose tolerance thus decreased in this group. Figure 2b) shows that the glucose reductions of ICR-MSG males at 12 weeks of age were significantly higher than the controls. Thus these males had insulin resistance.
Glucose tolerance test and insulin tolerance test
Blood chemistry
The blood concentrations of glucose, B-Ins, T-Cho, TG, LDL-Cho, HDL-Cho, AST, and ALT in non-fasted ICR-MSG mice at 29 and 54 weeks of age are shown in Table 1 . Most of blood concentration levels of the ICR-MSG male mice were higher than those of the controls, and ICR-MSG female mice had a similar tendency.
Organ weights
The weights of VWAT, IBAT, pancreas, and liver of the ICR-MSG mice and the controls at 29 and 54 weeks of age are shown in Table 2 . The weights of ICR-MSG mice at 29 and 54 weeks were significantly heavier than the controls. The weights of IBAT of ICR-MSG mice at 29 and 54 weeks were significantly heavier than the controls. The pancreas of the ICR-MSG mice of both sexes at 29 and 54 weeks did not differ from the controls. Figure 3 shows a light microscopic feature image of the pancreas of ICR-MSG males. Histologically, hypertrophy of the pancreatic islet was a characteristic of these mice. No major change was observed in the pancreas of control mice. Table 3 lists the pathological findings of pancreatic islets of both ICR-MSG and control mice at 29 and 54 weeks of age. In the ICR-MSG males and females, pancreatic islet hypertrophy was observed. In the ICR-MSG males and females (Table 4), the incidence of hepatic degeneration was higher in males than in females at 54 weeks of age. The incidence of hepatic neoplasms and foci of hepatic cellular alterations in ICR-MSG males were high, although these findings did not appear in females at all. No change was observed in the eye, the sciatic nerve, VWAT, IBAT, aorta, or cerebrum of either sex. In the control mice, no major changes were observed.
Pathology
Discussion
Olney [10] reported that a large injection of MSG into newborn mice generated necrosis of neuronal cells of the ventromedial nucleus and arcuate nucleus in the hypothalamus, and as a result, the mice developed polyphagia and obesity. However, ICR-MSG mice in this study showed no difference from controls in food intake at 6 weeks of age. The obesity was not caused by polyphagia. It was said by Iwase et al. [3] and Cameron et al. [1] that obesity without polyphagia is due to the amount and frequency of MSG injection.
There has been no report that normal ICR mice injected with MSG developed diabetes mellitus, however, we found an especially high rate of incidence (70%) of glycosuria in ICR-MSG males, and the levels of blood glucose and B-Ins concentration were also significantly high. A decrease in glucose tolerance and the appearance of insulin resistance were also observed in these males. These results confirm that ICR-MSG males develop obesity without polyphagia and Type 2 diabetes mellitus at a high rate. It was reported that the ventromedial nucleus of the hypothalamus was destroyed by injecting goldthioglucose (GTG) [6, 7] and that the mice showed polyphagia and obesity [8] , thereafter becoming diabetic (hyperglycemia, hyperinsulinemia, and hypertrophy of the pancreatic islet). These GTG mice showed the same diabetic condition as ICR-MSG mice, however, the rate of appearance was very low [4] , therefore, ICR-MSG mice are advantageous since a large number of obese diabetes mellitus mice without polyphagia can easily be produced.
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ICR-MSG mice at 54 weeks of age, in which the acceleration of insulin secretion was presumed because of an increase in insulin resistance. These results are very similar to those previously reported in spontaneously occurring obese type 2 diabetes mellitus model mice [2, 11, 12] . It was confirmed that the 54-week-old ICR-MSG males had maintained a type 2 diabetes mellitus condition for a long period because they showed the same symptoms of obesity, hyperglycemia, hyperinsulinemia, hypertrophy of pancreatic islets, and anomalous lipid value they had at 29 weeks of age. In contrast, few of these mice were observed to have atrophy of the pancreatic islets and insulitis. Insulin concentration in their blood was also low, suggesting the possibility of atrophy of the pancreatic islets because of the loss of B cells due to continuing insulin resistance. Additionally, neoplasms and foci of hepatic cellular alterations were observed in the liver of the ICR-MSG males. It was presumed that this was the result of long-term fatty degeneration of the hepatic cells induced by MSG, and it resulted in a tumor of the liver. The tumor found in this experiment was small in size, so the pathological degree of dysplasia was low and therefore did not greatly influence the diabetic condition of the ICR-MSG mice. With the condition of the ICR-MSG mice resembling human type 2 diabetes mellitus, they are viewed as a potential new, experimental model animal for diabetes mellitus.
